AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-137023274/johnson-johnson-pharmaceutical-research.html" title="Facts and information about Johnson & Johnson Pharmaceutical Research & Development LLC receives not approvable letter for Risperdal in the treatment of psychosis of Alzheimer's disease.">Johnson & Johnson Pharmaceutical Research & Development LLC receives not approvable letter for Risperdal in the treatment of psychosis of Alzheimer's disease.</a>
Close
Set up an RSS feed that alerts you when new articles from Asia Africa Intelligence Wire are available.
Frequently asked questions about RSS feeds
Johnson & Johnson Pharmaceutical Research & Development LLC receives not approvable letter for Risperdal in the treatment of psychosis of Alzheimer's disease.
(From Chemical Business NewsBase - Press Release)
Johnson & Johnson Pharmaceutical Research & Development LLC (J&JPRD) has received a not approvable letter from the US Food and Drug Administration (FDA) regarding a Supplemental New Drug Application (sNDA) for Risperdal (risperidone) in the treatment of psychosis of Alzheimer's disease. Recognizing that the unmet need in this area is great, …
Related articles from newspapers, magazines, journals, and more
-
- Johnson & Johnson Pharmaceutical Research & Development LLC receives FDA...
-
News wire article from: Asia Africa Intelligence Wire
November 18, 2003
700+ words
-
- Johnson & Johnson Pharmaceutical Research & Development LLC completes...
-
News wire article from: Asia Africa Intelligence Wire
January 24, 2005
700+ words
-
- Johnson & Johnson Pharmaceutical Research & Development LLC submits new drug...
-
News wire article from: Chemical Business Newsbase
July 30, 2008
700+ words
-
- Johnson & Johnson Pharmaceutical Research & Development LLC receives not...
-
News wire article from: Asia Africa Intelligence Wire
June 30, 2005
700+ words
-
- Johnson & Johnson Pharmaceutical Research & Development LLC submits New Drug...
-
News wire article from: Chemical Business Newsbase
October 24, 2008
700+ words
